Barron quits GSK to take CEO post at $3B biotech startup, leaving Wood to finish what he began Eisai takes baton from Biogen as next Alzheimer's prospect follows in Aduhelm's footprints Fierce JPM Week: After 'objectively astonishing' progress on mRNA, biotech looks to tinker with winning formula Sponsored: Engineering Biology: The Evolution of the Biopharma Industry Altos bursts out of stealth with $3B, a dream team C-suite and a wildly ambitious plan to reverse disease Bristol Myers, VCs launch new RNA therapeutics biotech Ceptur with $75M to silence pre-mRNA Fierce JPM Week: Bayer's new R&D chief wants to push past Aspirin legacy with innovation Sensorion sinks as lead hearing loss program flounders in phase 2 trial, calling future indications into question As Pfizer's Cibinqo grabs an FDA green light, JAK inhibitors' entry into the eczema market 'has split doctors' opinion: report Low-value care most common among systems with fewer primary care physicians, investor ownership Smith & Nephew kicks in $135M for 3D-printed, cementless knee implant maker Engage Surgical Did BMS set up a subsidiary to avoid paying $1.4B in U.S. taxes? The Senate finance chairman is on the case Featured Story | By Nick Paul Taylor Hal Barron is leaving GlaxoSmithKline. After four years as chief scientific officer, Barron is leaving to take up the CEO post at a deep-pocketed, wildly ambitious biotech startup—leaving Pfizer veteran Tony Wood in charge of the scientific side of the company. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Eisai made history last year as Biogen’s partner on Aduhelm, the first approved Alzheimer’s treatment in decades. And yes, they know the launch could have gone better. Luckily, they get a do-over. read more By Annalee Armstrong Messenger RNA, or mRNA, became a household name so quickly thanks to the COVID-19 vaccines by Pfizer-BioNTech and Moderna. Now, biotech is taking a moment to reflect on where the field goes from here. read more Sponsored by: Danaher Corporation Is biopharma ready to reap the rewards and realize the full potential of synthetic/engineering biology? Jennifer Honeycutt talks about how engineering biology with the right partners could provide new pathways to drug discovery and development, portable cell-free solutions for scalable industrial biomanufacturing on demand, and new preclinical testing methods for better science and smarter biopharma. read more By Nick Paul Taylor Altos Labs just redefined big in biotech. Where to start? The $3 billion in investor support? The C-suite staffed by storied leaders—Barron, Bishop, Klausner—identifiable by one name? Or the wildly ambitious plan to reverse disease for patients of any age? Altos is all that and more. read more By Kyle LaHucik Messenger RNA soared to the spotlight with the rollout of COVID-19 vaccines last year, and now a new biotech is looking at silencing pre-mRNA to target cancers, central nervous system diseases and other conditions. Bristol Myers Squibb and multiple venture capital shops are betting $75 million on Ceptur Therapeutics' launch. read more By Kyle LaHucik As head of global R&D for Bayer, Christian Rommel is attempting to chart a reinvention of research and development at the storied Big Pharma. Recent acquisitions, leadership additions and developments in technology will all have to work in his favor to bring Bayer into the next stage. read more By Kyle LaHucik Sensorion's sudden hearing loss med failed to beat placebo at improving hearing sensitivity, but the French biotech will stay mum on further development plans until secondary endpoint data is released in mid-March. read more By Ben Adams Pfizer believes it’s onto a $3 billion winner after the FDA approval of its dermatitis JAK inhibitor Cibinqo in January, but a new report surveying physicians around the world shows prescribing this class of meds may be a tricky sell for reps. read more By Dave Muoio A recent Johns Hopkins analysis of Medicare claims identified health systems delivering the most low- and no-value medical services to seniors. read more By Andrea Park No bone cement, no problem. Smith & Nephew will now offer both cemented and cementless partial knee implants, thanks to the recent acquisition of Engage Surgical and its cement-free technology. read more By Eric Sagonowsky Tax avoidance allegations have hovered over major players in the pharmaceutical industry for decades. Some of the biggest names in the business have occasionally faced inquiries or have had to pay up to the Internal Revenue Service. Now, Bristol Myers Squibb is at the center of a U.S. Senator's tax probe. read more Resources Sponsored by: WIRB-Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. Immuno-Oncology 360° Summit March 16-18, 2022 | New York Marriott Brooklyn Bridge Fierce JPM Week 2022 January 18-20, 2022 | Virtual Event Fierce Drug Safety Summit February 8-9, 2022 | Arlington, VA | Presented by Fierce Pharma
February 16-17, 2022 | Virtual Fierce BD&L Summit for Life Sciences March 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Medical Affairs Strategic Summit (MASS) East April 12-14, 2022 | New Brunswick, NJ Fierce Health IT Summit April 20, 2022 | Virtual Event Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Leaders in Life Sciences Summit May 16-17, 2022 | Boston, MA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Next-Gen June 29, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce Biotech Forum October 2022 | Location TBD Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 2022 | Location TBD | 